{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.1","value":"104.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.2","value":"99.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Week 35 n=41"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Waist circumference was one of the measurements of clinical signs of CD","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Baseline and week 35","title":"Waist Circumference at Week 35","type":"SECONDARY","unitOfMeasure":"cm"}